DocGo (NASDAQ:DCGO) Price Target Cut to $1.00 by Analysts at Canaccord Genuity Group

DocGo (NASDAQ:DCGO) had its target price cut by Canaccord Genuity Group from $1.50 to $1.00 in a research report report published on Wednesday morning,Benzinga reports. They currently have a hold rating on the stock.

Several other research analysts have also commented on the stock. Stifel Nicolaus decreased their price objective on shares of DocGo from $4.00 to $2.50 and set a “buy” rating for the company in a report on Tuesday, March 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DocGo in a research note on Monday, December 29th. Needham & Company LLC reissued a “buy” rating and issued a $3.00 price target on shares of DocGo in a research note on Tuesday, March 17th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $3.00 price objective on shares of DocGo in a report on Tuesday, March 17th. Three analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $2.38.

DocGo Stock Down 5.1%

Shares of DCGO stock opened at $0.61 on Wednesday. The stock has a fifty day moving average of $0.74 and a 200 day moving average of $0.99. DocGo has a 52 week low of $0.59 and a 52 week high of $2.82. The firm has a market capitalization of $60.32 million, a price-to-earnings ratio of -0.33 and a beta of 0.95.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DCGO. Millennium Management LLC lifted its holdings in shares of DocGo by 878.6% during the third quarter. Millennium Management LLC now owns 766,210 shares of the company’s stock valued at $1,042,000 after purchasing an additional 687,911 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of DocGo by 205.4% in the 4th quarter. Goldman Sachs Group Inc. now owns 805,427 shares of the company’s stock worth $707,000 after buying an additional 541,670 shares during the last quarter. AQR Capital Management LLC increased its position in DocGo by 219.1% during the 1st quarter. AQR Capital Management LLC now owns 476,645 shares of the company’s stock valued at $1,258,000 after buying an additional 327,269 shares in the last quarter. JPMorgan Chase & Co. increased its position in DocGo by 92.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 557,613 shares of the company’s stock valued at $758,000 after buying an additional 267,259 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in DocGo by 81.2% during the fourth quarter. Renaissance Technologies LLC now owns 565,535 shares of the company’s stock valued at $496,000 after buying an additional 253,400 shares during the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

About DocGo

DocGo, Inc is a U.S.-based integrated healthcare company that delivers on-demand and mobile healthcare services. The company’s business model centers on deploying customized medical clinics paired with a digital care platform to bring primary and acute care directly to patients. Through a combination of telemedicine and over-the-road medical units, DocGo addresses routine medical exams, chronic disease management, occupational health screenings, specialist consultations and urgent care interventions.

In addition to its mobile clinic fleet, DocGo’s digital platform offers 24/7 virtual care, facilitating remote consultations via video, phone or secure messaging.